P. Murali Doraiswamy, Duke University Health System
Around the globe, more than 45 million people suffer from Alzheimer’s disease. The progressive dementia costs the U.S. alone hundreds of billions of dollars a year and numbers are expected to keep rising as baby boomers age. With a high failure rate in new Alzheimer’s drugs—more than 99 out of every 100 proposed new drugs fails in clinical trials—it’s clear that we need new approaches to study and manage this disease.
That’s where mobile technology comes in. There are has been a rapid growth in smart phone and internet access among the elderly – for example, over 40% of older adults in the US and Europe own a smart phone or tablet and some 70% use the internet. While the percentages are much smaller in the developing world, they are rising fast.
Here’s how researchers are turning to mobile devices to help cure Alzheimer’s:
1) Clinical trials involving early Alzheimer’s. Many Alzheimer’s trials being conducted today rely on patients who have very early stages of disease; scientists want to know whether drugs or other interventions can help prevent these patients from developing full-blown dementia. Finding patients who fit the bill for these trials, however, is costly and time-consuming. Mobile apps—including the Apple Research Kit and the Android-based Research Stack—can help by:
- Giving the general public a way to find out about and become involved in clinical trials.
- Providing an easy way for scientists to reach many people at once.
- Enrolling people in clinical trials; these apps allow participants to sign up and answer initial screening questions without time-consuming clinic visits.
2) Administering memory tests. In the past, researchers have used pen-and-paper memory and cognition tests to diagnose and track the progression of Alzheimer’s disease. In the future, these tests will increasingly be given on mobile device screens, whether in a clinic or in the comfort of someone’s home. These tests will eventually:
- Be used as endpoints in clinical trials, telling researchers whether their intervention is making a difference in patients’ disease. Already, the FDA (in the U.S.) has cleared several mobile cognitive tests for use as clinical tools.
- Act as screening tests to find people who may have Alzheimer’s disease and refer them for further examination and care or enroll them in a clinical trial.
- Help clinicians follow the progression of a patient’s disease and determine whether medications or other interventions need to be altered.
3) Tracking patients’ behavior. Phone, GPS, and wearable sensorsare also beginning to offer new ways to collect data about the functional abilities of people with Alzheimer’s—how they carry out daily living. In the near future, mobile devices may be able to measure such things as:
- A patient’s spatial orientation
- The ability of someone to perform basic financial calculations
- How well a person can drive, use a phone and computer, or adhere to their medication schedule.
4) Helping patients and caregivers find support. Social mediaapps offer ways for researchers to raise awareness of Alzheimer’s, enhance patient engagement, and for patients or caregivers to share experiences. And trial sponsors are increasingly using ride-sharing apps like Uber and Lyft to help Alzheimer’s patients and caregivers reach clinical trial locations more conveniently.
5) Treating Alzheimer’s. Aside from research, mobile phone apps are now being developed that provide users with games and puzzles challenging their memory and attention. For example, Duke Health System and Columbia are conducting a clinical trial to test the benefits of playing computerized brain games and computerized crossword puzzles in people with mild cognitive impairment. People in the study will get brain scans as well as standard tests of daily functions to see how people improve. While the jury is still out on whether using these apps as “digital vaccines” can delay the onset of dementia, but most argue that they certainly can’t hurt.
Please sign in or register for FREE
If you are a registered user on Nature Portfolio Health Community, please sign in